AstraZeneca Sees COVID Vaccine Trial Dropouts Due To Pfizer, Moderna Authorizations In US
Approximately 9% of subjects have withdrawn from the 32,000-person trial because they were eligible to receive one of the mRNA vaccines in the US; AstraZeneca expects limited impact on efficacy assessment but is working on a potential plan for crossover of all participants to try to keep as many in the study as possible for safety follow-up.
You may also be interested in...
More than 5% of participants in J&J’s vaccine trial chose to be unblinded because they were eligible to receive a vaccine that had already gained a US FDA emergency use authorization.
A conditional marketing authorization for AstraZeneca/Oxford's COVID-19 vaccine came just hours after the European Medicines Agency’s CHMP voted unanimously to recommend it on Friday.
Pfizer relies on investigators to determine when prioritization recommendations apply, Moderna offers unblinding to everyone.